- Home
- OLMA
as 07-26-2024 4:00pm EST
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 506.8M | IPO Year: | 2020 |
| Target Price: | $22.80 | AVG Volume (30 days): | 719.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.78 - $17.79 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Olema Pharmaceuticals Inc. (OLMA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Harmon Cyrus | OLMA | Director | Jun 28 '24 | Sell | $10.77 | 20,000 | $215,400.00 | 761,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | May 31 '24 | Sell | $9.41 | 15,000 | $141,150.00 | 791,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | May 31 '24 | Sell | $10.93 | 5,000 | $54,650.00 | 786,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | May 31 '24 | Sell | $12.33 | 5,000 | $61,650.00 | 781,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | May 6 '24 | Sell | $10.92 | 5,000 | $54,600.00 | 806,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Apr 30 '24 | Sell | $9.51 | 15,000 | $142,650.00 | 811,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Mar 28 '24 | Sell | $10.97 | 20,000 | $219,400.00 | 826,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Feb 29 '24 | Sell | $12.41 | 24,900 | $309,009.00 | 846,383 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Feb 29 '24 | Sell | $13.00 | 100 | $1,300.00 | 846,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Jan 31 '24 | Sell | $12.23 | 25,000 | $305,750.00 | 876,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Jan 31 '24 | Sell | $15.56 | 5,000 | $77,800.00 | 871,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Dec 29 '23 | Sell | $13.30 | 22,500 | $299,250.00 | 903,783 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Dec 29 '23 | Sell | $14.10 | 2,500 | $35,250.00 | 901,283 | SEC Form 4 |
| Paradigm Biocapital Advisors LP | OLMA | 10% Owner | Dec 6 '23 | Buy | $11.60 | 100,000 | $1,160,000.00 | 6,590,981 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Nov 30 '23 | Sell | $12.57 | 25,000 | $314,250.00 | 926,283 | SEC Form 4 |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Nov 20 '23 | Sell | $14.83 | 7,261 | $107,680.63 | 37,959 | SEC Form 4 |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Nov 20 '23 | Sell | $15.33 | 200 | $3,066.00 | 37,759 | SEC Form 4 |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Nov 20 '23 | Sell | $13.89 | 7,095 | $98,549.55 | 30,664 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 '23 | Sell | $14.87 | 6,776 | $100,759.12 | 580,952 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 '23 | Sell | $15.32 | 200 | $3,064.00 | 580,752 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 '23 | Sell | $13.89 | 6,653 | $92,410.17 | 574,099 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Nov 20 '23 | Sell | $14.86 | 4,192 | $62,293.12 | 955,272 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Nov 20 '23 | Sell | $13.90 | 3,989 | $55,447.10 | 951,283 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 8 '23 | Sell | $17.61 | 200 | $3,522.00 | 561,270 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 1 '23 | Sell | $15.02 | 6,668 | $100,153.36 | 565,343 | SEC Form 4 |
Latest Olema Pharmaceuticals Inc. News
OLMA Breaking Stock News: Dive into OLMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barrons.com
a month ago
TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors
GlobeNewswire
2 months ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Olema Oncology to Participate in Upcoming Investor Conferences in June
Simply Wall St.
2 months ago
Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
2 months ago
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
GlobeNewswire
3 months ago
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Compare OLMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.